# EDGAR Filing Document

**Accession Number:** 0001827401
**File Stem:** 0002060755-26-000002
**Filing Date:** 2026-1
**Character Count:** 4651
**Document Hash:** d0efb26bf62dcff07f261a84df444dd8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002060755-26-000002.hdr.sgml**: 20260105

**ACCESSION NUMBER**: 0002060755-26-000002

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260105

**FILED AS OF DATE**: 20260105

**DATE AS OF CHANGE**: 20260105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRIGHT MINDS BIOSCIENCES INC.
- **CENTRAL INDEX KEY:** 0001827401
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40997
- **FILM NUMBER:** 26507915

**BUSINESS ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013
- **BUSINESS PHONE:** 6474072515

**MAIL ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013

**UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **January 2026**

Commission File No. **001-40997**

**BRIGHT MINDS BIOSCIENCES INC.**<br>(Translation of registrant's name into English)

---

| | |
|:---|:---|
| **400 N Aberdeen St Suite 900**<br>**Chicago, IL 60642**<br>(U.S. Corporate headquarters) | **1122 Mainland St #228**<br>**Vancouver, BC V6B 5L1**<br>(Canadian Corporate headquarters) |

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [ ] **Form 40-F [ X ]**

------

**SUBMITTED HEREWITH**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibits** |  |
| 99.1 | [News Release dated](ex991-20260105.htm)[January](ex991-20260105.htm)[5](ex991-20260105.htm)[, 202](ex991-20260105.htm)[6](ex991-20260105.htm) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BRIGHT MINDS BIOSCIENCES INC.**

*/s/ Ryan Cheung*

Ryan Cheung<br>Chief Financial Officer

Date: January 5, 2026

------

## Exhibit 99.1

------

**For Immediate Release**

**Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026**

– Conference Call and Live Webcast at 8AM ET –

-

NEW YORK CITY and VANCOUVER, British Columbia, January 5, 2026 – Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) ("Bright Minds" or the "Company"), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy.

**Webcast Information**

The Bright Minds virtual event will be webcast live and a replay will be available after the event by visiting the "Investors" section of the Company's website and selecting "Events and Presentations."

**Date and Time:** January 6, 2026, 8AM ET

**Webcast:** https://app.livestorm.co/bright-minds-biosciences/bmb-101-topline-data-announcement

The call will include a discussion of the data followed by a Q&A session. Individuals who wish to ask questions should use the "Questions" tab available during the live webcast.

**About Bright Minds Biosciences**

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including Rare Epilepsy, Prader-Willi Syndrome, Depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

**Contact**

Alex Vasilkevich

Chief Operating Officer

Bright Minds Biosciences Inc.

------

T: 414-731-6422

E: alex@brightmindsbio.com

**Investor Relations**

Lisa M. Wilson

T: 212-452-2793

E: lwilson@investorrelations.com

------